Strug­gling Mar­i­nus gets a bump out of a pos­i­tive PhII snap­shot

A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and on­ly — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing af­ter it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­net­ic ail­ment.

In­ves­ti­ga­tors flipped the first card of its Phase II hand for ganax­olone in treat­ing CD­KL5, which trig­gers se­vere seizures and neu­ro­log­i­cal dam­age among the chil­dren af­flict­ed by it. One of four pa­tients had to drop out from a lack of re­sponse, but in­ves­ti­ga­tors say that the three oth­ers ex­pe­ri­enced a re­duc­tion in seizures rang­ing from 52% to 88%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.